 |
|
Study shows pine bark naturally decreases severe chronic venous insufficiency
July 13, 2006Research shows Pycnogenol® more effective than Daflon® in reducing leg swelling, walking pain
Recent findings published in the journal of Clinical and Applied Thrombosis/Hematosis show a significant symptom reduction of chronic venous insufficiency (CVI) in patients after supplementing with Pycnogenol® (pic-noj-en-all), an antioxidant plant extract from the bark of the French maritime pine tree. Over 35 years of research on Pycnogenol® demonstrate the antioxidant's ability to improve blood flow and strengthen venous walls. Published results from this study showed Pycnogenol® to be more effective in reducing edema (leg swelling), tight calves, skin alterations, pain during walking and swelling limbs than Daflon®, a combination of diosmin and hesperidin and a commonly prescribed drug used to treat CVI.
About 500,000 people in the United States develop leg ulcers due to CVI. If left untreated, leg and ankle swelling can lead to dangerous conditions such as deep vein thrombosis (DVT). Previous studies have shown Pycnogenol® to be effective in encouraging improved circulation and helping to prevent travel-related DVT. Like varicose veins, spider veins also develop if edema is left untreated.
"Chronic venous insufficiency is caused when leg veins cannot pump enough blood back into the heart. When people are not active, blood pools in their leg veins, legs and ankles can become swollen," said Peter Rohdewald, Ph.D. and researcher of the study. "Eventually, some of the valves cannot hold the weight of excessive blood, which then adds more pressure onto the next valve further downwards. Ultimately, the inability to prevent the liquid in the blood from seeping into the tissue is what causes edema, a common condition of CVI."
Researchers at L'Aquila University in Italy conducted a comparative analysis by supplementing 86 patients with severe CVI with Pycnogenol® and Daflon®. Each group supplemented daily for eight weeks. Patients who supplemented with Pycnogenol® received either 150 mg or 300 mg, while Daflon® patients supplemented with 1000 mg.
Ankle swelling was measured before 10 a.m. to avoid the swelling effect of standing and again after 30 minutes of resting with feet elevated. Measurements were taken at the beginning of the study and after four and eight weeks of treatment. A composite, analogue score based on signs and symptoms (edema, pain, restless limbs, subjective swelling, and skin alterations/redness) was recorded by patients. A second evaluation of edema was made by another physician.
After eight weeks of treatment, patients who supplemented with Pycnogenol® experienced decreased ankle swellings by 35 percent, while Daflon treatment decreased ankle swelling by 19 percent. A composite score for edema including pain, restless legs, feeling of heavy swollen legs, and skin alterations was found to be decreased with Pycnogenol® by 64%, whereas Daflon® was only half as effective, lowering the composite edema score by 32%.
The transdermal oxygen and carbon dioxide concentration in the lower legs was estimated with small sensors attached to the skin. Pycnogenol® treatment was found to significantly increase tissue oxygen and lower CO2, suggesting a considerable improvement in blood circulation to the legs. Daflon®, in contrast, did not yield any significant effect on the tissue oxygenation and apparently does not improve blood circulation to the legs.
"Interestingly, this study demonstrated that supplementation with a very high dosage of 300 mg Pycnogenol® a day did not yield significantly better effects than treatment with 150 mg Pycnogenol®, with the exception of the composite edema score, which improved better with the higher dosage," said Rohdewald.
Continuous stretching from CVI permanently enlarges veins. Past studies have shown that treating edema with Pycnogenol® prevents the development of spider veins. Pycnogenol® also helps prevent existing spider veins from getting larger and more prominent. When edema is successfully treated, the increased pressure on veins gets normalized, preventing the veins from further increasing in size.
"Pycnogenol® has demonstrated its efficacy and safety in several clinical trials and symptoms of CVI have been reduced significantly by Pycnogenol® in controlled studies. We were pleased to see that not only did Pycnogenol® decrease CVI symptoms, but the results were significantly more successful then the prescription drug used for treating CVI," said Rohdewald.
MWW Group
"Chronic venous insufficiency is caused when leg veins cannot pump enough blood back into the heart. When people are not active, blood pools in their leg veins, legs and ankles can become swollen," said Peter Rohdewald, Ph.D. and researcher of the study. "Eventually, some of the valves cannot hold the weight of excessive blood, which then adds more pressure onto the next valve further downwards. Ultimately, the inability to prevent the liquid in the blood from seeping into the tissue is what causes edema, a common condition of CVI."
Researchers at L'Aquila University in Italy conducted a comparative analysis by supplementing 86 patients with severe CVI with Pycnogenol® and Daflon®. Each group supplemented daily for eight weeks. Patients who supplemented with Pycnogenol® received either 150 mg or 300 mg, while Daflon® patients supplemented with 1000 mg.
Ankle swelling was measured before 10 a.m. to avoid the swelling effect of standing and again after 30 minutes of resting with feet elevated. Measurements were taken at the beginning of the study and after four and eight weeks of treatment. A composite, analogue score based on signs and symptoms (edema, pain, restless limbs, subjective swelling, and skin alterations/redness) was recorded by patients. A second evaluation of edema was made by another physician.
After eight weeks of treatment, patients who supplemented with Pycnogenol® experienced decreased ankle swellings by 35 percent, while Daflon treatment decreased ankle swelling by 19 percent. A composite score for edema including pain, restless legs, feeling of heavy swollen legs, and skin alterations was found to be decreased with Pycnogenol® by 64%, whereas Daflon® was only half as effective, lowering the composite edema score by 32%.
The transdermal oxygen and carbon dioxide concentration in the lower legs was estimated with small sensors attached to the skin. Pycnogenol® treatment was found to significantly increase tissue oxygen and lower CO2, suggesting a considerable improvement in blood circulation to the legs. Daflon®, in contrast, did not yield any significant effect on the tissue oxygenation and apparently does not improve blood circulation to the legs.
"Interestingly, this study demonstrated that supplementation with a very high dosage of 300 mg Pycnogenol® a day did not yield significantly better effects than treatment with 150 mg Pycnogenol®, with the exception of the composite edema score, which improved better with the higher dosage," said Rohdewald.
Continuous stretching from CVI permanently enlarges veins. Past studies have shown that treating edema with Pycnogenol® prevents the development of spider veins. Pycnogenol® also helps prevent existing spider veins from getting larger and more prominent. When edema is successfully treated, the increased pressure on veins gets normalized, preventing the veins from further increasing in size.
"Pycnogenol® has demonstrated its efficacy and safety in several clinical trials and symptoms of CVI have been reduced significantly by Pycnogenol® in controlled studies. We were pleased to see that not only did Pycnogenol® decrease CVI symptoms, but the results were significantly more successful then the prescription drug used for treating CVI," said Rohdewald.
MWW Group
A rare case of ischemic colitis caused by chronic venous insufficiency
Ischemic injury to the bowel is a well known disease entity that has a wide spectrum of pathological and clinical findings. A sudden drop in the colonic blood supply is key to its development.
Damaged veins heal faster with heparin treatment, laboratory study finds
A commonly used medication that prevents blood clots from forming may also prevent existing clots from damaging delicate vein walls - and may accelerate healing in a clot-damaged area of vein wall, according to new research from the University of Michigan Cardiovascular Center.
Breakthrough in understanding of hereditary disease of lymphatic vessels
(Helsinki, August 22nd) -- A study from the Ludwig Institute for Cancer Research (LICR) Affiliate Center at the University of Helsinki in Finland has shed light on the development of lymphatic vasculature and valves, and may help to develop better treatments for lymphedema. The disease, which results from damaged or absent lymphatic vessels, may be inherited or may be a side-effect of the surgical removal of tumors. Lymphatic vessels normally remove fluid and proteins escaping from blood capillaries into surrounding tissues, and lymphedema is characterized by the disabling swelling of legs, and sometimes arms, that results when the lymphatic vessels are unable to clear the lymph from the ti
More Chronic Venous Insufficiency Current Events and Chronic Venous Insufficiency News Articles
 |
Chronic Venous Insufficiency: Diagnosis and Treatment by Jeffrey L. Ballard (Editor), John J. Bergan (Editor) Chronic venous insufficiency, manifesting as disabling open leg ulcers, lipodermatosclerosis and severe cutaneous hyperpigmentation is thought to affect five percent of the population over age 80 and a significant proportion, probably greater than one percent, of Western populations under age 65. To date little has been known about how to treat this condition cost-effectively beyond supportive and palliative care. Thus, the most important feature of Chronic Venous Insufficiency is that it describes the interventions which markedly ameliorate, and in some cases cure, the condition. The authoritative text has been skilfully illustrated to show how new methods of endovascular and endoscopic interventions can be integrated with radiologic techniques to correct totally the... |
 |
Natrol ActiVin, Grape Seed Extract, 50 mg, Tablets - 120 count by Natrol One of nature's most unique antioxidants, easy-to-take, vegetarian tablets. A Dietary Supplement. Help your body fight free radicals with all-natural ActiVin™, a high-potency grape seed extract rich in biologically active flavonoids - one of the most unique antioxidants yet discovered. Antioxidants can help prevent the cellular damage caused by free radicals.* ActiVin™ products are produced using the environmentally safe Acti-Pure™ method. Instead of using toxic solvents and/or harsh chemicals, Acti-Pure™ utilizes a high-tech water and ethanol extraction process which preserves the natural balance of biologically active flavonoids. Each Tablet Contains: 50mg - ActiVin™ (Grape Seed Extract). * This statement has not been evaluated by... |
|
Horse chestnut seed extract for chronic venous insufficiency.(Alternative medicine: an evidence-based approach): An article from: Family Practice News by Nancy Walsh (Author) This digital document is an article from Family Practice News, published by International Medical News Group on December 15, 2004. The length of the article is 985 words. The page length shown above is based on a typical 300-word page. The article is delivered in HTML format and is available in your Amazon.com Digital Locker immediately after purchase. You can view it with any web browser. Citation Details Title: Horse chestnut seed extract for chronic venous insufficiency.(Alternative medicine: an evidence-based approach) Author: Nancy Walsh Publication: Family Practice News (Magazine/Journal) Date: December 15, 2004 Publisher: International Medical News Group Volume: 34 Issue: 24 Page: 52(1) Distributed by Thomson... | |
 |
Natrol Grape Seed Extract, 50mg, 60 Capsules (Pack of 2) by Natrol Dietary Supplement. Natrol's Grape Seed Extract contains naturally occurring proanthocyanidins which exhibit anti-oxidant properties.* Proanthocyanidins are measured by the amount of total Oligomeric Proanthocyanidin content or |
 |
Microcirculation in Chronic Venous Insufficiency: 15th Bodensee Symposium on Microcirculation, Lindau, June 19-21, 1998 (Progress in Applied Microcirculation) by K. Messmer (Editor) Chronic venous insufficiency is a widespread disease of great socioeconomic relevance. It is characterized by accompanying venous hypertension due to valvular dysfunction orvalvular insufficiency. Analysis of the tissue surrounding venous ulcers has demonstrated intra- and perivascular accumulation of leukocytes, probably activated by tissue hypoxia. These microcirculatory phenomena have attracted the interest of researchers in the field of basic and clinical microcirculation. The papers in this text are taken from the 15th Bodensee Symposium on Microcirculation, and aim to bring together a panel of specialists from the basic physiologic and clinical sciences in order to discuss the available data related to microcirculation and chronic venous insufficiency. The presentations include... |
|
Investigations of Patients with Deep Vein Thrombosis and Chronic Venous Insufficiency by Andrew N. Nicolaides (Author), David S. Sumner (Author) | |
 |
Chronic Venous Insufficiency - A Medical Dictionary, Bibliography, and Annotated Research Guide to Internet References by ICON Health Publications (Author) In March 2001, the National Institutes of Health issued the following warning: "The number of Web sites offering health-related resources grows every day. Many sites provide valuable information, while others may have information that is unreliable or misleading." Furthermore, because of the rapid increase in Internet-based information, many hours can be wasted searching, selecting, and printing.This book was created for medical professionals, students, and members of the general public who want to conduct medical research using the most advanced tools available and spending the least amount of time doing so. |
 |
Twinlab Grape Seed Extract, 100mg, Capsules, 30 ea by Twinlab Grape seed extract is a natural antioxidant and a rich source of bioflavonoids. |
|
Horse chestnut seed extract for chronic venous insufficiency.(AN EVIDENCE-BASED APPROACH): An article from: Internal Medicine News by Nancy Walsh (Author) This digital document is an article from Internal Medicine News, published by International Medical News Group on December 1, 2004. The length of the article is 997 words. The page length shown above is based on a typical 300-word page. The article is delivered in HTML format and is available in your Amazon.com Digital Locker immediately after purchase. You can view it with any web browser. Citation Details Title: Horse chestnut seed extract for chronic venous insufficiency.(AN EVIDENCE-BASED APPROACH) Author: Nancy Walsh Publication: Internal Medicine News (Magazine/Journal) Date: December 1, 2004 Publisher: International Medical News Group Volume: 37 Issue: 23 Page: 46(1) Distributed by Thomson... | |
|
Bilateral impedance plethysmography during the active phase as a method for diagnosing chronic venous insufficiency (University Scholar project) by James A Davies (Author) |
| © 2009 BrightSurf.com |